Horizon Pharma receives NOA for patent app covering PENNSAID

|About: Horizon Pharma plc (HZNP)|By:, SA News Editor

The USPTO issues a Notice of Allowance (NOA) for Horizon Pharma's (NASDAQ:HZNP) patent application number 13/665,790 titled, "Treatment of Pain with Topical Diclofenac" which covers PENNSAID (diclofenac sodium topical solution) 2%.

The U.S. patent, when issued, will be effective until July 10, 2029. It is the eleventh patent covering PENNSAID.